CoVBio
acquired
acquired
Stage
About
CoVBio developed booster vaccines and therapeutics targeting SARS‑CoV‑2 and related sarbecoviruses, including a pan‑sarbecovirus booster vaccine intended to protect against future variants and animal-to-human crossovers. The company was acquired by Leyden Labs in 2024.
Explore CoVBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.